康泰生物(300601.SZ):一季度扣非淨利潤預增2483.83%-3060.38%
格隆匯4月13日丨康泰生物(300601.SZ)公佈2022年第一季度業績預吿,公司預計實現歸屬於上市公司股東的淨利潤為2.5億元-3億元,同比增長893.93%-1092.72%;預計實現扣除非經常性損益後的淨利潤為2.24億元-2.74億元,同比增長2483.83%-3060.38%。
業績變動原因:
報吿期內,公司按照年度經營計劃積極開展各項工作,以市場為導向,有序推進產品研發和生產,進一步加強市場銷售及推廣工作,經營業績實現了良好的增長態勢。2022年一季度公司主要產品四聯苗銷售收入較上年同期增長約231.35%,乙肝疫苗銷售收入較上年同期增長約33.24%;此外,較上年同期相比,公司新增銷售產品13價肺炎球菌多糖結合疫苗,致使公司淨利潤較去年同期實現較大幅度增長。
本報吿期預計非經常性損益對淨利潤的影響金額約為2591.96萬元,去年同期非經常性損益的金額為1648.02萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.